ATAGI have released new guidance for healthcare providers regarding the administration of Japanese encephalitis virus (JEV) vaccines. These recommendations follow on from earlier advice from CDNA identifying the groups at highest risk of disease and who should be prioritised for vaccination.
The guidance includes:
- vaccine brand and dosing recommendations
- priority populations
- advice for women who are pregnant or breastfeeding
- 加强剂量
- co-administration with other vaccines
- common and expected side effects following vaccination
To read the ATAGI recommendations in full, please click on the link below:
ATAGI 日本脑炎病毒疫苗临床指南
For further information on JEV, including background on disease and common vaccine questions, please click on the link below:
MVEC: JEV